Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cardiome -- CRME -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (126)	1/22/2007 11:29:16 AM
From: tuck	Read Replies (3) \| Respond to of 285

>>Cardiome Pharma Corp. announces exercise of over-allotment option Monday January 22, 9:00 am ET NASDAQ: CRME TSX: COM VANCOUVER, Jan. 22 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that the underwriters of its cross-border public offering of 8,000,000 common shares that was priced on January 18, 2007, exercised the over-allotment option in full to purchase an additional 1,200,000 common shares at a price of US$10.50 per share. Net proceeds from the offering (including the common shares to be issued pursuant to the exercise of the over-allotment option) are expected to be approximately US$90 million. Bear, Stearns & Co. Inc. acted as book-running manager, CIBC World Markets Inc. acted as co-lead manager and Canaccord Adams Inc. and Leerink Swann & Company acted as co-managers for the offering. Raymond James Ltd., Orion Securities Inc. and Sprott Securities Inc. were also part of the underwriting syndicate. The offering is expected to close on or about January 23, 2007, subject to customary conditions.<< snip I didn't get filled on a lowball bid for shares after the offering was first announced, and my sold puts expired . . . so, no position, but looking for yet another entry. Cheers, Tuck